INTRODUCTION

Fibromyalgia (FM) syndrome, characterized by chronic diffuse muscle pain, skin sensitivity, sleep disturbance, depression, anxiety, and fatigue [1], is also accompanied by a variety of other symptoms, including migraines, interstitial cystitis, irritable bowel syndrome and vasospastic symptoms [2]. Vasospastic symptoms in FM include Raynaud’s phenomenon and intolerance to cold, caused by decreased microcirculatory blood flow above tender points [3]. Therefore, slight morphological changes in nailfold capillaries may occur in FM patients [4].

Nailfold capillaroscopy (NFC), a modality used to diagnose secondary Raynaud’s phenomenon, can be used to examine morphological and functional microcirculation changes in connective tissue diseases (CTDs) [5].
Raynaud’s phenomenon develops during early-stage CTD; it is observed in 80% to 90% of systemic sclerosis (SSc) patients such that early diagnosis is very important. Examination of the nailfold capillaries can reveal the nature and extent of microvascular pathology in patients with CTD. Several prominent nailfold capillary changes, including mega-capillary, capillary hemorrhage, and loss of capillary distribution, are clearly apparent in SSc [6]. Several studies have examined NFC patterns in FM patients, including a report from Morf et al. [4]. However, compared to SSc, there has been insufficient research concerning findings on NFC, although many FM patients suffer from Raynaud’s-like symptoms. Therefore, this study compared NFC findings between FM patients and healthy controls, and investigated NFC patterns in FM and the association between these patterns and the clinical features of FM.

METHODS
Patient selection
A total of 67 patients were randomly selected from those fulfilling the 1990 American College of Rheumatology (ACR) criteria for FM, who first visited our outpatient clinic; 30 age- and sex-matched healthy controls were also included in this study.

Investigations of clinical manifestations
Clinical parameters included tender point count, Fibromyalgia Impact Questionnaire (FIQ) score [7], arthralgia, headache, sensations of numbness or coldness, irritable bowel syndrome, dry eyes, and dry mouth. The FIQ comprises 10 brief, self-administered scales as follows: physical impairment, feeling good, missing work, completing work, pain, fatigue, feeling rested, stiffness, anxiety, and depression.

Nailfold capillaroscopy
Before the nailfold test, patients were seated inside the procedure room for a minimum of 15 minutes to adapt to the room temperature of 20°C to 25°C. Each patient was seated such that the dorsum of their hand was facing upwards, with halogen lights illuminating the nails (coated with immersion oil) under nailfold microscopy. The NFC test was performed by a skilled examiner who was not aware of the patients’ clinical status. Patients’ nailfolds, of the second, third and fourth digits of both hands, were observed under a light microscope (×100 and ×400 magnifications; Olympus SZ-PT, Olympus, Tokyo, Japan). A digital camera (Polaroid, Minnetonka, MN, USA) transmitted all microphotographs to a computer; after the images were saved, they were enhanced using color filtering via the Adobe Photoshop version 7.0 (Adobe Systems Inc., San Jose, CA, USA). For quantitative analysis, we counted the total number of capillaries, and the number of deletions, within a 3-mm-wide area of the central part of the digits [8]. The outcomes were recorded as average values for six digits. Furthermore, an experienced rheumatologist measured the apical limb width, and the capillary width, of three capillary rings located at the center (where the resolution is most-fine), directly from a computer screen and from all six digits. By measuring the capillary boundary at a capillary length of 25 µm (1 cm; ×400) we defined the capillary dimension as the total number of pixels in the designated area (Fig. 1) [6], using the Adobe Photoshop version 7.0.

Statistical analysis
All results are expressed as median values and interquartile ranges. For statistical analysis, the SPSS version 13.0 (SPSS Inc., Chicago, IL, USA) was used. We used the Mann-Whitney U test to compare NFC parameters and
FIQ scores; Fisher exact test and the chi-square test were used to compare clinical manifestations between the FM patient and control groups. Spearman correlation coefficient was used to assess the relationship between NFC measurement parameters and FIQ scores. A \( p < 0.05 \) was taken to indicate statistical significance.

**RESULTS**

**Demographic and clinical characteristics of fibromyalgia patients**

We included a total of 67 FM patients and 30 healthy controls. The mean age of the 67 FM patients was 41.97 years, compared to 37.26 years in the 30 healthy controls. There were 63 females (94%) in the FM group; all 30 healthy controls were female. Mean body mass index was marginally higher in the FM group (22.46 kg/m\(^2\)) compared to the control group (21.9 kg/m\(^2\)). A total of six FM patients (8.96%) had Raynaud’s phenomenon, which represents a significantly higher prevalence rate compared to that of the control participants (none of whom had Raynaud’s phenomenon). The mean duration of Raynaud’s phenomenon in the FM group was 8.1 months (Table 1).

The most frequent symptom observed in the FM group was arthralgia (\( n = 47, 70.1\% \)) followed by headache (\( n = 39, 58.2\% \)), numbness (\( n = 38, 56.7\% \)) and peripheral coldness (\( n = 34, 50.7\% \)). Other symptoms or syndromes in the FM patients included irritable bowel syndrome (\( n = 31, 48.3\% \)), dry eye (\( n = 20, 29.0\% \)), and dry mouth (\( n = 15, 22.4\% \)). More than 50% of the FM group were full-time housewives; 41 of this group (61.2%) were working from home, whereas 26 (38.8%) had other occupations. Six (9.0%) of these FM patients were employees, three (4.5%) were laborers, five (7.5%) were operators, and 12 (17.9%) had other jobs. A total of 47 (70.1%) FM patients were married and 24 (35.8%) were postmenopausal (Table 2).

**FIQ scores in fibromyalgia participants**

FIQ was designed to assess the current health status of FM patients across diverse domains, including physical function and symptoms. The FIQ consists of 10 subscales, the first of which comprises 11 items related to the

---

**Table 1. Demographic characteristics and features of Raynaud’s phenomenon in the control and fibromyalgia syndrome groups**

| Characteristic                        | Healthy control (n = 30) | Fibromyalgia syndrome (n = 67) |
|---------------------------------------|-------------------------|--------------------------------|
| Female sex                            | 30 (100%)               | 63 (94%)\(^a\)                |
| Median age, yr                        | 37.26                   | 41.07\(^b\)                   |
| Body mass index, kg/m\(^2\)          | 21.98                   | 22.46\(^c\)                   |
| Raynaud’s phenomenon                  | 0                       | 6 (8.96%)                     |
| Duration of Raynaud’s phenomenon, mon | 0                       | 8.1                           |

\(^a\)\( p < 0.05 \), fibromyalgia vs. control group.

**Table 2. Clinical and demographic characteristics of the fibromyalgia syndrome group (n = 67)**

| Characteristic                        | No. (%) |
|---------------------------------------|---------|
| Association symptom                  |         |
| Arthralgia                            | 47 (70.1) |
| Headache                              | 39 (58.2) |
| Numbness sensation                    | 38 (56.7) |
| Peripheral coldness                   | 34 (50.7) |
| Irritable bowel syndrome symptom      | 31 (48.3) |
| Dry eye                               | 20 (29.9) |
| Dry mouth                             | 15 (22.4) |
| Job                                   |         |
| Housewife                             | 41 (61.2) |
| Employee                              | 6 (9.0) |
| Laborer                               | 3 (4.5) |
| Operator                              | 5 (7.5) |
| Others                                | 12 (17.9) |
| Marriage                              | 47 (70.1) |
| Postmenopause                         | 24 (35.8) |
performance of physical functions that require significant muscular exertion. The second and the third subscales are concerned with the number of days on which patients felt well, and the number of days on which they were unable to work (including housework) due to FM symptoms. Subscales 4 to 10 represent horizontal linear scales assessing work difficulty, pain, fatigue, morning tiredness, stiffness, anxiety, and depression [9]. Our FM groups completed the FIQ subscales concerned with their physical functionality and symptoms (Table 3).

**Nailfold capillary microscopic features in the FM and healthy control groups**
We conducted the NFC test on both the FM and healthy control groups. The FM patients had an average of 17.3 ± 1.7 loops in the 3-mm-wide area of the central part of their digits, compared to an average of 21.8 ± 2.9 loops in the control group. The average number of loop deletions was 2.2 ± 0.9 in the FM group, compared to 0.6 ± 0.7 in the healthy controls (Table 4). It appears that FM patients had a lower number of capillaries, but higher deletion scores compared to the healthy controls on NFC. The average apical width (µm) of the FM patients was 1.1 ± 0.2; their mean capillary width (µm) was 5.4 ± 0.5. In the control group, the average apical width was 3.7 ± 0.6; their capillary width was 7.7 ± 1.4 (Table 4). Both apical limb and capillary width were significantly decreased in FM patients, indicating that FM patients have abnormally decreased digital capillary diameter and density.

However, capillary dimension (total number of pixels measured using Adobe Photoshop) did not differ between the FM and control groups. The mean capillary dimension of the FM group was 524.1 pixels; in the control group it was 515.7 pixels (Table 4). This suggests that the length or tortuosity of capillaries in FM patients is increased to compensate for diminished microcirculation.

**Correlation between clinical manifestation and nailfold capillary microscopic parameters**
To compare the FIQ scores of each group with their NFC results, we assessed the correlations between clinical manifestations and NFC parameters; as shown in Table 5, among the FIQ parameters, only subscale 1 (physical function) was negatively correlated with capillary dimension ($r = -0.248, p = 0.048$); there were no other significant associations between NFC patterns and other FIQ subscale scores.

### Table 3. Fibromyalgia Impact Questionnaire scores in the fibromyalgia syndrome group (n = 67)

| Questionnaire score       | Median |
|---------------------------|--------|
| Q1 (0–3, physical)        | 1.02   |
| Q2 (0–7, feel good)       | 3.07   |
| Q3 (0–7, work missed)     | 1.60   |
| Q4 (0–10, do job)         | 5.58   |
| Q5 (0–10, pain)           | 6.25   |
| Q6 (0–10, fatigue)        | 6.81   |
| Q7 (0–10, rested)         | 6.74   |
| Q8 (0–10, stiffness)      | 6.82   |
| Q9 (0–10, anxiety)        | 6.30   |
| Q10 (0–10, depression)    | 6.01   |

### Table 4. Microscopic nailfold capillary characteristics

| Characteristic                          | Healthy controls (n = 30) | Fibromyalgia syndrome (n = 67) | $p$ value$^b$ |
|-----------------------------------------|---------------------------|-------------------------------|--------------|
| NFC feature, median                     |                           |                               |              |
| No. of loops (within a 3-mm region)     | 21.8                      | 17.3                          | $< 0.05$     |
| No. of loop deletions                   | 0.6                       | 2.2                           | $< 0.05$     |
| Apical width, µm                        | 3.7                       | 1.1                           | $< 0.05$     |
| Capillary width, µm                     | 7.7                       | 5.4                           | NS           |
| Capillary dimension$^a$                 | 515.7                     | 524.1                         | NS           |

NFC, nailfold capillaroscopy; NS, not significant.

$^a$Capillary dimension is presented as the total pixel number.

$^b$p < 0.05.
DISCUSSION

FM is a chronic pain syndrome defined by widespread pain for > 3 months and the presence of ≥ 11 of 18 tender points [10]. In 2010, the ACR announced revised FM diagnostic criteria, designed for primary and specialty care, to diagnose FM simply and practically and to provide a severity scale for characteristic FM symptoms, without use of the classic tender point examination [1,11]. The majority of FM patients complain of sleep disturbance, emotional distress, and pronounced fatigue [1,2,12]. FM represents the extreme end of the musculoskeletal pain spectrum in the general population. Several studies have demonstrated that this muscle pain is due to muscle ischemia, caused by decreased muscular blood flow and microcirculatory abnormality [13,14]. Numerous recent studies emphasize the role of central nervous system (CNS) pain processing abnormalities in FM, including central sensitization, hyperalgesia, and inadequate pain inhibition [15,16]. Therefore, the necessity of investigating pain modulation in the CNS continues to increase [17]. FM patients also suffer from numerous other chronic pain syndromes, which contribute to pain impulses and may serve to maintain central sensitization, including irritable bowel syndrome, temporomandibular disorder, migraine, low back pain, and peripheral coldness (e.g., Raynaud’s phenomenon) [15].

Although the etiology of FM is not yet fully understood, the data suggest that FM may stem from autonomic nervous system dysfunction [18]; drugs that influence the autonomic system are being studied as potential treatments of FM [19]. Changes in autonomic nervous system function are known to accompany various diseases, including irritable bowel syndrome, chronic fatigue syndrome, migraine and other vasospastic symptoms [2,20]. Vasospastic symptoms, such as Raynaud’s phenomenon and cold intolerance, occur in approximately 36% of patients with primary FM. NFC is a useful tool to evaluate Raynaud’s phenomenon, by examining microcirculation abnormalities in other connective diseases [5]. A previous study showed that FM patients had fewer capillaries in the nailfold (p < 0.001), significantly more capillary dilatations (p < 0.05), irregular formations (p < 0.01), and markedly reduced (p < 0.001) peripheral blood flow compared to healthy controls [4]. These data suggest that there are morphological abnormalities in microcirculation in FM, which can cause vasospastic symptoms.

We conducted this study to determine NFC patterns in FM, and their association with clinical features. A previous study indicated abnormalities in capillary numbers, dilatations and formations in FM on NFC. In addition to these parameters, we measured capillary dimension by calculating the number of pixels using the Adobe Photoshop software package [6]. In our study, FM patients had fewer capillaries, higher deletion scores and significantly decreased apical and capillary widths on NFC compared to healthy controls, which indicates that FM patients have abnormally decreased digital capillary diameter and density. Interestingly, there was no group difference in capillary dimension, which suggests that the length and tortuosity of capillaries in FM patients is increased to compensate for diminished microcirculation.

We observed that FM patients had altered capillary density and diameter in the digits; because FM is a dis-
ease characterized by unremarkable pathogenesis (and requires further study), diminished microcirculation on NFC may help to explain FM symptoms such as peripheral coldness, and may cause hormonal and biochemical abnormalities in FM pathogenesis that could lead to the development of advanced treatments for FM.

KEY MESSAGE

1. Diminished microcirculation and increased nailfold capillary tortuosity may explain fibromyalgia symptoms, such as peripheral coldness.

Conflict of interest
No potential conflict of interest relevant to this article was reported.

Acknowledgments
This research was supported by a fund from Soonchunhyang University.

REFERENCES

1. Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res 2016;68:600-610.
2. Cohen H, Neumann L, Kotler M, Buskila D. Autonomic nervous system derangement in fibromyalgia syndrome and related disorders. Isr Med Assoc J 2001;3:755-760.
3. Vaeroy H, Helle R, Forre O, Kass E, Terenius L. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 1988;32:21-26.
4. Morf S, Amann-Vesti B, Forster A, et al. Microcirculation abnormalities in patients with fibromyalgia: measured by capillary microscopy and laser fluxmetry. Arthritis Res Ther 2005;7:R209-R216.
5. Wu PC, Huang MN, Kuo YM, Hsieh SC, Yu CL. Clinical applicability of quantitative nailfold capillaroscopy in differential diagnosis of connective tissue diseases with Raynaud’s phenomenon. J Formos Med Assoc 2013;112:482-488.
6. Kim HS, Park MK, Kim HY, Park SH. Capillary dimension measured by computer-based digitalized image correlated with plasma endothelin-1 levels in patients with systemic sclerosis. Clin Rheumatol 2016;29:247-254.
7. Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol 1991;18:728-733.
8. Cutolo M, Sulli A, Pizzorni C, Accardo S. Nailfold video-capillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol 2006;33:155-160.
9. Bennett R. The Fibromyalgia Impact Questionnaire (FIQ): a review of its development, current version, operating characteristics and uses. Clin Exp Rheumatol 2005;23(5 Suppl 39):S154-S162.
10. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-172.
11. Lee SS. Newer diagnostic criteria of fibromyalgia and its clinical implications. J Rheum Dis 2011;18:35-160.
12. Wolfe F, Walitt BT, Katz RS, Hauser W. Symptoms, the nature of fibromyalgia, and diagnostic and statistical manual 5 (DSM-5) defined mental illness in patients with rheumatoid arthritis and fibromyalgia. PLoS One 2014;9:e88740.
13. Elvin A, Siosteen AK, Nilsson A, Kosek E. Decreased muscle blood flow in fibromyalgia patients during standardised muscle exercise: a contrast media enhanced colour Doppler study. Eur J Pain 2006;10:137-144.
14. Kasikcioglu E, Dinler M, Berker E. Reduced tolerance of exercise in fibromyalgia may be a consequence of impaired microcirculation initiated by deficient action of nitric oxide. Med Hypotheses 2006;66:950-952.
15. Staud R. Biology and therapy of fibromyalgia: pain in fibromyalgia syndrome. Arthritis Res Ther 2006;8:268.
16. Borsook D, Burstein R, Becerra L. Functional imaging of the human trigeminal system: opportunities for new insights into pain processing in health and disease. J Neurobiol 2004;61:127-125.
17. Kim SH, Song J, Mun H, Park KU. Effect of the combined use of tramadol and milnacipran on pain threshold in an animal model of fibromyalgia. Korean J Intern Med 2009;24:139-142.
18. da Cunha Ribeiro RP, Roschel H, Artioli GG, et al. Cardiac autonomic impairment and chronotropic incompetence in fibromyalgia. Arthritis Res Ther 2011;13:R190.
19. Kulshreshtha P, Gupta R, Yadav RK, Bijlani RL, Deepak...
KK. Effect of low-dose amitriptyline on autonomic functions and peripheral blood flow in fibromyalgia: a pilot study. Pain Med 2012;13:131-136.

20. Sarzi-Puttini P, Atzeni F, Di Franco M, et al. Dysfunction-al syndromes and fibromyalgia: a 2012 critical digest. Clin Exp Rheumatol 2012;30(6 Suppl 74):143-151.